← Back to Search

Neuromodulator

OLD (4 U per 0.1 mL) for Frown Lines

Phase < 1
Waitlist Available
Led By John Joseph, MD
Research Sponsored by Clinical Testing of Beverly Hills
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 180 days
Awards & highlights

Study Summary

This trial is comparing how long two different concentrations of Xeomin take to work on reducing frown lines for women in the US.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~180 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 180 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Response Duration
Secondary outcome measures
Change from Baseline Score
Change in Frontalis Function
Investigator Live Assessment (At Rest)
+3 more

Trial Design

2Treatment groups
Active Control
Group I: OLD (4 U per 0.1 mL)Active Control1 Intervention
Participants will receive a total Xeomin dose of 20U using a 4U per 0.1mL concentration divided into 5 intramuscular injections performed once.
Group II: COLD (4 U per 0.05 mL group)Active Control1 Intervention
Participants will receive a total Xeomin dose of 20U using a 4U per 0.05mL concentration divided into 5 intramuscular injections performed once.

Find a Location

Who is running the clinical trial?

Clinical Testing of Beverly HillsLead Sponsor
3 Previous Clinical Trials
100 Total Patients Enrolled
Merz North America, Inc.Industry Sponsor
63 Previous Clinical Trials
8,762 Total Patients Enrolled
John Joseph, MDPrincipal InvestigatorClinical Testing of Beverly Hills
6 Previous Clinical Trials
158 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there still opportunities for patients to join this clinical experiment?

"According to the clinicaltrials.gov website, no participants are being sought for this study at present. The medical research initiative was posted on May 1st 2022 and revised most recently on March 30th 2022; nonetheless, there remain 9 other trials in need of volunteers currently."

Answered by AI
Recent research and studies
Plastic and Reconstructive SurgeryJournal
Consensus Recommendations on the Use of Botulinum Toxin Type A in Facial Aesthetics
Carruthers, Jean, Steven Fagien, and Seth L. Matarasso. 2004. “Consensus Recommendations on the Use of Botulinum Toxin Type A in Facial Aesthetics”. Plastic and Reconstructive Surgery. Ovid Technologies (Wolters Kluwer Health). doi:10.1097/01.prs.0000144795.76040.d3.
Clinical Interventions in AgingJournal
Onset, Longevity, and Patient Satisfaction with Incobotulinumtoxina for the Treatment of Glabellar Frown Lines: A Single-arm, Prospective Clinical Study
Prager, Welf, Bee, Havermann, and Zschocke. 2013. “Onset, Longevity, and Patient Satisfaction with Incobotulinumtoxina for the Treatment of Glabellar Frown Lines: A Single-arm, Prospective Clinical Study”. Clinical Interventions in Aging. Informa UK Limited. doi:10.2147/cia.s34854.
clinicaltrials.govStudy
Xeomin Treatment of Glabellar Lines Using OLD Versus COLD
2022. "Xeomin Treatment of Glabellar Lines Using OLD Versus COLD". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05305768.
~14 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top